Case studies
Working with our customers to reduce time to market, deliver on quality, provide deep therapeutic expertise, and enhance R&D ROI.
Highlights
We focus our innovation on the factors that matter most — accelerating time to market, reducing costs and enhancing quality. Learn more about how we've helped clients meet and exceed their goals in this selected library of case studies.
Proactive patient retention strategy in a GLP-1 RA trial
Explore how ICON successfully supported a sponsor’s cardiovascular outcome trial for a GLP-1 receptor agonist with 9,900+ patients with type 2 diabetes and maintained a retention rate of 97% over 7 years.
A small biotech success story
A small US-based biotech company was in a race to be the first to market with their lead targeted oncology product.
FSP partnership - sustained efficiency and ongoing innovation
The implementation of an FSP model across our partner's project management function, led to 20% cost efficiences and a 30% reduction in client burden.
By taking a site and patient-centric approach, and leveraging advanced tools and real-time data insights, we maximise patient access, recruitment, and retention—ensuring that every trial is conducted with efficiency, agility, and a commitment to improving patient outcomes.
All case studies
Filter our case studies by categories, selecting amongst our broad range of solutions.
Language Services: Voiceover and video localisation
ICON provided a fully localised and tested informational solution for patients that was consistent across platform components for online materials developed to train patients on the consent process.
Launching into an established market
ICON Market Access played a key role in informing a client’s go-to-market strategy, including analytics around market sizing, a competitive landscape assessment and a benefit design analysis for a long-acting, injectable anti-psychotic drug.
.jpg?crop=yes&w=2048&h=1077&a=0,145&itok=xDnn4e_W "Oncology care in commercial positioning"){kind=icon}
Chronic Myeloid Leukaemia
As a result of the multifaceted communication approach with sites and a strong partnership between ICON and sponsor, the study met its protocol-specified enrolment goal just 9 days beyond contracted Last Patient In date (LPI).
Electronic implementation and digital app localisation
ICON delivered a multifaceted omnichannel awareness campaign to provide a seamless customer experience between print and digital channels for a drug to treat PPD.
Driving payer education and awareness
ICON delivered a multifaceted omnichannel awareness campaign to provide a seamless customer experience between print and digital channels for a drug to treat PPD.
Rapid manuscript development and delivery
Through close collaboration with a client, the ICON team provided the support necessary to advance a critical COVID-19 manuscript from outline through submission to acceptance in only 20 days.
PKU-specific HRQol Questionnaire Development & Validation
ICON developed the first PKU-specific Quality of Life questionnaire available and validated in four age groups and seven languages.
Retrospective Chart Review Study in Patients with Osteoporosis
This study was conducted to describe clinical characteristics and current treatment practices for patients with osteoporosis at high risk factor in Japan.
Leveraging Immuno-Oncology real world data
ICON supported a randomised phase 3 study to examine the study drug in combination with nivolumab vs chemotherapy in patients with checkpoint inhibitor refractory non-squamous NSCLC.
Successful adaptation to complex dose escalation
ICON was selected by a mid-size biotech company to support a phase 1 dose escalation and cohort expansion study of an immune checkpoint inhibitor, in patients with advanced solid tumors. Mid-study, the sponsor was acquired by a large pharma company to which ICON has efficiently supported the transition to the evolving sponsor business model and operations.
Human Cytomegalovirus Vaccine Development
A pharmaceutical client needed to better understand patient perspectives, concerns and awareness of that could impact the development of a vaccine for Human Cytomegalovirus (HCMV).
H1N1 vaccine study
A sponsor approached ICON during an influenza pandemic in Mexico to conduct a randomised, placebo controlled vaccine study with an investigative pandemic H1N1 vaccine.
Let's collaborate
Discover how ICON's expertise transforms clinical trials.